At the American Association for Cancer Research (AACR) 2014 meeting, Puma Biotechnology (NYSE:PBYI) presented additional data on their Phase II ISPY2 study that evaluated Neratinib + Paclitaxel against Herceptin + Paclitaxel as treatment for breast cancer in the neo-adjuvant setting. On December 4, PBYI reported the graduation of the Neratinib + Paclitaxel regimen from the ISPY2 study. At AACR, the company provided more detail on the prior news including that only the HER2+ hormone receptor [HR] negative group had graduated. In addition, PBYI provided color on pathological complete response (pCR) rates, safety data, and biomarker outcomes.
pCR Results from the HER2+ HR Negative and HER2+ HR Negative/HR Positive Subgroups
In the HER2+ HR negative group, PBYI reported...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|